{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T23:12:37Z","timestamp":1769123557822,"version":"3.49.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.ijcard.2019.05.048","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T08:23:03Z","timestamp":1558599783000},"page":"159-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Efficacy and safety of combined neprilysin and RAS inhibition in heart failure: A meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"293","author":[{"given":"Qiang","family":"Geng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sufang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengzhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongqiang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2019.05.048_bb0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1042\/CS20150469","article-title":"The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment","volume":"130","author":"Volpe","year":"2016","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.ijcard.2019.05.048_bb0010","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ijcard.2014.08.032","article-title":"Natriuretic peptides and cardio-renal disease","volume":"176","author":"Volpe","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2019.05.048_bb0015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the omapatrilat cardiovascular treatment vs. Enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ijcard.2019.05.048_bb0020","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"PARADIGM-HF investigators and committees. angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2019.05.048_bb0025","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2019.05.048_bb0030","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/FJC.0000000000000485","article-title":"Efficacy and safety of crystalline valsartan\/sacubitril (LCZ696) compared to placebo and combinations of free valsartan and sacubitril in patients with systolic hypertension: the RATIO study","volume":"69","author":"Izzo","year":"2017","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ijcard.2019.05.048_bb0035","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin\u2013neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2019.05.048_bb0040","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jclinepi.2012.04.012","article-title":"GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence","volume":"66","author":"Brunetti","year":"2013","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.ijcard.2019.05.048_bb0045","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(00)02602-7","article-title":"Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial","volume":"356","author":"Rouleau","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2019.05.048_bb0050","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/01.CIR.0000029801.86489.50","article-title":"Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2019.05.048_bb0055","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.116.08556","article-title":"Effects of sacubitril\/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: the PARAMETER study","volume":"69","author":"Williams","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.ijcard.2019.05.048_bb0060","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ijcard.2019.05.048_bb0065","unstructured":"National Institutes of Health; Norvartis Phamaceuticals. ClinicalTrials.gov [Internet]. Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension. Bethesa, MD: National Institutes of Health; Norvartis Phamaceuticals; 2013. Identifier NCT 01785472. https:\/\/ClinicalTrials.gov\/show\/NCT01785472."},{"key":"10.1016\/j.ijcard.2019.05.048_bb0070","unstructured":"National institutes of Health, Novartis Pharmaceuticals. ClinicalTrials.gov [Internet]. Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension. Bethesa, MD: National institutes of Health, Novartis Pharmaceuticals; 2013. Identifier NCT01599104. https:\/\/ClinicalTrials.gov\/show\/NCT01599104."},{"key":"10.1016\/j.ijcard.2019.05.048_bb0075","unstructured":"National Institutes of Health; Novartis Phamaceuticals. ClinicalTrials.gov [Internet]. Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension. Bethesa, MD: National Institutes of Health; Novartis Phamaceuticals; 2012. Identifier NCT01615198. https:\/\/Clini calTrials.gov\/show\/NCT01615198."},{"key":"10.1016\/j.ijcard.2019.05.048_bb0080","unstructured":"Novartis Pharmaceuticals. ClinicalTrials.gov [Internet]. Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan. Bethesda, MD: Novartis Pharmaceuticals; 2013. Identifier NCT01876368. https:\/\/ClinicalTrials.gov\/show\/NCT01876368."},{"key":"10.1016\/j.ijcard.2019.05.048_bb0085","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.jacc.2007.09.021","article-title":"Natriuretic peptides","volume":"50","author":"Daniels","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2019.05.048_bb0090","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jacc.2016.05.011","volume":"68","author":"Yancy","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2019.05.048_bb0095","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2019.05.048_bb0100","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/1074248417693379","article-title":"The effects of LCZ696 in patients with hypertension compared with angiotensin receptor blockers: a meta-analysis of randomized controlled trials","volume":"22","author":"Zhao","year":"2017","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.ijcard.2019.05.048_bb0105","doi-asserted-by":"crossref","first-page":"83323","DOI":"10.18632\/oncotarget.18312","article-title":"Safety of the neprilysin\/renin-angiotensin system inhibitor LCZ696","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527319312136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527319312136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:42:35Z","timestamp":1759092155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527319312136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":21,"alternative-id":["S0167527319312136"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2019.05.048","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of combined neprilysin and RAS inhibition in heart failure: A meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2019.05.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}